Generex Biotech Cash Flow - Annual (OTCMKTS:GNBT)

Add to My Stocks
$1.97 $0.06 (3.14%) GNBT stock closing price Sep 18, 2018 (Closing)

The financial analysis of GNBT requires an investor to check the cash flows for Generex Biotech. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Generex Biotech profits one has to check the income statement and for Generex Biotech debt one has to check the balance sheet. Generex Biotech had cash and cash equivalents of $- at beginning of the year and $2.87M at year end for 2017. Generex Biotech cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Generex Biotech saw a outflow of $- from investing activities for 2017.

View details of Generex Biotech cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Aug - Jul2017201620152014201320122011201020092008
Net Income Cash Flow
-76.83M-3.22M-2.19M--8.55M-9.49M-21.67M-25.27M-45.81M-36.22M
Depreciation Depletion Amortization Cash-Flow13.38M---1.3M1.21M--17.45M4.77M
Net Increase (Decrease) in Assets Liabilities-1.1M-0.19M-0.59M--0.57M3.15M2.1M--0.46M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net61.28M1.08M-0.87M-3.34M3.38M---5.45M3.61M
Net Cash from (used by) Operating Activities
-1.17M-0.77M-2.88M-3.57M-3.66M-8.04M-16.93M-22.31M-22.64M-28.3M
Increase (Decrease) in Prop Plant And Equipment----1.76M4.95M-0.05M-0.15M--0.05M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments--------8.85M5.16M
Other Cash Inflow (Outflow) from Investment Activities---0.09M-0.08M-0.07M-0.17M-0.23M-0.22M-0.15M-0.18M
Net Cash from (used by) Investment Activities
---0.09M-1.68M4.77M-0.28M-0.38M8.69M4.92M
Issuance (Purchase) of Equity Shares3.05M--4.95M4.46M2M6.25M22.47M15.61M-
Issuance (Repayment) of Debt Securities----0.6M-1M-1.25M-0.12M-0.13M-0.11M19.63M
Increase (Decrease) in Bank & Other Borrowings---------4.5M-
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
4.03M--4.35M3.46M-6.13M22.33M10.99M19.65M
Effect of Exchange Rate Changes on Cash-0.01M-0.01M-0.02M-0.01M-0.02M-0.03M---0.08M-0.05M
Net Change in Cash & Cash Equivalents
2.86M-0.73M-2.51M1.56M1.46M-2.55M-11.08M-0.31M-3.04M-3.78M
Cash & Equivalents at Beginning of Year--3.26M1.7M-2.79M13.88M14.19M17.23M21.02M
Cash & Equivalents at Year End2.87M--3.26M1.7M-2.79M13.88M14.19M17.23M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Generex Biotech stock comparison chart provides an easy way to compare the stock price with peers along with details of Generex Biotech stock price history.
The statement of cash flows can be categorized into three main sections:

  • Generex Biotech saw a positive change in Net Change in Cash and Cash Equivalents of $2.86M in 2017. Apart from the Generex Biotech stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Generex Biotech lost $-1.17M cash from operations. It is important to check this to see where the company is getting its money from.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $- for GNBT stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash flow from financing activities shows the flow of cash between Generex Biotech and its owners and creditors and was $4.03M for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Generex Biotech Cash Flow

FCF margin
0

Annual Cash Flow Statements For Generex Biotechnology Corporation Peers

Aoxing Pharma cash flow, COTINGA PHARMA cash flow, MannKind cash flow, Novo Nordisk cash flow, Acerus Pharma cash flow